AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33278935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg every 3 weeks plus nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin)
Number of subjects: 847
Study 33278935 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 847
Study 33278935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 847
Study 33660114 — intervention group
Group type: EXPERIMENTAL
Intervention: Black seed raisin (90 g per day)
Number of subjects: 38
Study 33942294 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of randomized controlled trial abstracts according to CONSORT guidelines
Number of subjects: 0
Study 33942294 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34446500 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet non-invasive ventilation (NIV) with usual care
Number of subjects: 320
Study 34446500 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study 35686512 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational digital video disc plus routine education
Number of subjects: 120
Study 35686512 — intervention group
Group type: COMPARATOR
Intervention: Routine education only
Number of subjects: 120
Study 33439284 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication technology enhanced transition coordinator intervention
Number of subjects: 203
Study 33439284 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study 32352493 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8.CNGA3 gene therapy (1.0 × 10^10, 5.0 × 10^10, or 1.0 × 10^11 total vector genomes)
Number of subjects: 9
Study 32352493 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8.CNGA3 gene therapy
Number of subjects: 9
Study 36280159 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized TNQ
Number of subjects: 127
Study 36280159 — intervention group
Group type: COMPARATOR
Intervention: Without TNQ
Number of subjects: 127
Study 33257457 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (5-9 medications)
Number of subjects: 1761
Study 33257457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolypharmacy (10-14 medications)
Number of subjects: 1761
Study 33257457 — intervention group
Group type: EXPERIMENTAL
Intervention: Super hyperpolypharmacy (≥15 medications)
Number of subjects: 1761
Study 33257457 — intervention group
Group type: COMPARATOR
Intervention: Control group (<5 medications)
Number of subjects: 1761
Study 35465777 — intervention group
Group type: EXPERIMENTAL
Intervention: MINDS Optimal Health Program (OHP) - nine sessions over twelve months
Number of subjects: 106
Study 35465777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 33397442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy
Number of subjects: 110
Study 33397442 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression protocol after alemtuzumab induction therapy
Number of subjects: 110
Study 35380498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smokers
Number of subjects: 44
Study 35380498 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS users
Number of subjects: 44
Study 35380498 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 44
Study 33952416 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Engage (S‐ENG)
Number of subjects: 62
Study 33952416 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 62
Study 35576292 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 930
Study 35576292 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (lactobacillus rhamnosus)
Number of subjects: 930
Study 33243723 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session body image intervention delivered by teachers
Number of subjects: 1495
Study 33243723 — intervention group
Group type: COMPARATOR
Intervention: Lessons-as-usual control
Number of subjects: 1495
Study 91032514 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine 5 microgram
Number of subjects: 0
Study 91032514 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine 2 microgram
Number of subjects: 0
Study 35051671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 204
Study 34237425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 25% replacement of corn
Number of subjects: 240
Study 34237425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 50% replacement of corn
Number of subjects: 240
Study 34237425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 75% replacement of corn
Number of subjects: 240
Study 34237425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 100% replacement of corn
Number of subjects: 240
Study 34237425 — intervention group
Group type: COMPARATOR
Intervention: Control (0% glycerol replacement)
Number of subjects: 240
Study 35810756 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy alone
Number of subjects: 408
Study 35810756 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase plus thrombectomy
Number of subjects: 408
Study 34708555 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diuretic protocol (Phase 2) based on HFA algorithm, starting with intravenous administration of two times the oral home dose.
Number of subjects: 500
Study 34708555 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Phase 1)
Number of subjects: 500
Study 32205206 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 75
Study 32205206 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogenic Collagen Matrix (XCM)
Number of subjects: 75
Study 35148750 — intervention group
Group type: EXPERIMENTAL
Intervention: Heallagen® (7 g L-arginine, 7 g L-glutamine, 1.5 g HMB)
Number of subjects: 60
Study 35148750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 60
Study 35273045 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision thresholds (DTs) derived from the GRADE EtD frameworks
Number of subjects: 0
Study 35273045 — intervention group
Group type: COMPARATOR
Intervention: Judgments made by guideline panels
Number of subjects: 0
Study 34620663 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 5532
Study 34620663 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing starting at age 30
Number of subjects: 5532
Study 34620663 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended screening interval of 4-5 years
Number of subjects: 5532
Study 34620663 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive screen test result
Number of subjects: 5532
Study 34620663 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5532
Study 35718307 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise delivered via Telehealth (Coviu) for eight weeks by an Accredited Exercise Physiologist in a group setting.
Number of subjects: 160
Study 35718307 — intervention group
Group type: COMPARATOR
Intervention: Usual care (receiving physical activity guidelines).
Number of subjects: 160
Study 35772447 — intervention group
Group type: EXPERIMENTAL
Intervention: VPM1002
Number of subjects: 416
Study 35772447 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 416
Study 32809014 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 402
Study 32809014 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 402
Study 32809014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 402
Study 32809014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 402
Study 32822653 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Number of subjects: 56
Study 32822653 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor
Number of subjects: 56
Study 32822653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 35511290 — intervention group
Group type: EXPERIMENTAL
Intervention: xenogenic bone + autogenous bone (ratio 70:30)
Number of subjects: 36
Study 35511290 — intervention group
Group type: EXPERIMENTAL
Intervention: xenogenic bone + L‐PRF
Number of subjects: 36
Study 35511290 — intervention group
Group type: EXPERIMENTAL
Intervention: xenogenic bone
Number of subjects: 36
Study 32533742 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation programme (six face-to-face interventions)
Number of subjects: 238
Study 32533742 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (six routine prenatal examinations)
Number of subjects: 238
Study 36301306 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM combined with stretching
Number of subjects: 54
Study 36301306 — intervention group
Group type: COMPARATOR
Intervention: PBM
Number of subjects: 54
Study 36301306 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretching
Number of subjects: 54
Study 36301306 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 54
Study 34863358 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA1273 (Moderna)
Number of subjects: 2878
Study 34863358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (Janssen)
Number of subjects: 2878
Study 34863358 — intervention group
Group type: EXPERIMENTAL
Intervention: half VLA (Valneva)
Number of subjects: 2878
Study 34863358 — intervention group
Group type: COMPARATOR
Intervention: Control (MenACWY)
Number of subjects: 2878
Study 34863358 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCov-19 (Oxford-AstraZeneca)
Number of subjects: 2878
Study 34863358 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (Pfizer-BioNtech)
Number of subjects: 2878
Study 34254530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified induction with high-doses cytarabine (1500 mg/m2 b.i.d. on days 5-7 of induction)
Number of subjects: 0
Study 34254530 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not specified)
Number of subjects: 0
Study 34508370 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion
Number of subjects: 34
Study 36275698 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPs‐MTX (intrapleural infusion of tumor cell-derived microparticles packaging methotrexate)
Number of subjects: 86
Study 36275698 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 86
Study 36275698 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPs‐MTX
Number of subjects: 86
Study 36275698 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 86
Study 36275698 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPs‐MTX and Saline (both groups)
Number of subjects: 86
Study 34588689 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 (AZD1222) vaccine
Number of subjects: 264
Study 35100251 — intervention group
Group type: EXPERIMENTAL
Intervention: Wang Nam Yen herbal tea
Number of subjects: 120
Study 35100251 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 120
Study 35100251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32008913 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (∼630 g/week)
Number of subjects: 131
Study 32008913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts (∼200 g/week)
Number of subjects: 131
Study 32008913 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet, restricting fatty fish and nuts)
Number of subjects: 131
Study 36171614 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and Provider driven Social Accountability Intervention (CaPSAI)
Number of subjects: 16
Study 36171614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 33427674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivation process intervention
Number of subjects: 1240
Study 33427674 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement first (cultivation process)
Number of subjects: 1240
Study 33427674 — intervention group
Group type: COMPARATOR
Intervention: Social support only
Number of subjects: 1240
Study 35322650 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial Digital Impression Group (ADIG)
Number of subjects: 56
Study 35322650 — intervention group
Group type: COMPARATOR
Intervention: Axial Conventional Impression Group (ACIG)
Number of subjects: 56
Study 35322650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted Digital Impression Group (TDIG)
Number of subjects: 56
Study 35322650 — intervention group
Group type: COMPARATOR
Intervention: Tilted Conventional Impression Group (TCIG)
Number of subjects: 56
Study 34558247 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (20 minutes, once every other day for 8 weeks)
Number of subjects: 120
Study 34558247 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride tablets (5 mg once a day for 8 weeks)
Number of subjects: 120
Study 33331989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg/day
Number of subjects: 452
Study 33331989 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 452
Study 33331989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib with dose reduction(s)
Number of subjects: 452
Study 32964776 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 30
Study 32964776 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 34338309 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric 11 Gracey curet tip
Number of subjects: 4
Study 34338309 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracey curet
Number of subjects: 4
Study 34338309 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric scaler
Number of subjects: 4
Study 34338309 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 4
Study 34086033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 4781
Study 34086033 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4781
Study 34086033 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 4781
Study 32731987 — intervention group
Group type: COMPARATOR
Intervention: Positive Control (PC)
Number of subjects: 300
Study 32731987 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (NC)
Number of subjects: 300
Study 32731987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase A (250, 500, 750, 1,000 FTU/kg)
Number of subjects: 300
Study 32731987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase B (250, 500, 750 FTU/kg)
Number of subjects: 300
Study 32731987 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase C (500, 750, 1,000 FTU/kg)
Number of subjects: 300
Study 35438304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) delta-9 tetrahydrocannabinol (THC) at 0.015 mg/kg
Number of subjects: 42
Study 35438304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) delta-9 tetrahydrocannabinol (THC) at 0.03 mg/kg
Number of subjects: 42
Study 35438304 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) placebo
Number of subjects: 42
Study 33618930 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 524
Study 33618930 — intervention group
Group type: COMPARATOR
Intervention: Usual advice
Number of subjects: 524
Study 32771013 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (500 IU/kg intravenously every other day for 2 weeks)
Number of subjects: 1285
Study 35667722 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended office BP measurement
Number of subjects: 630
Study 35667722 — intervention group
Group type: COMPARATOR
Intervention: Attended office BP measurement
Number of subjects: 630
Study 35667722 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP monitoring (HBPM) for sleep BP
Number of subjects: 630
Study 35667722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep BP on HBPM
Number of subjects: 630
Study 34627009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg daily)
Number of subjects: 64
Study 34627009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32334578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 167
Study 32334578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 167
Study 32334578 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 167
Study 32334578 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 167
Study 33899261 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared oral care intervention
Number of subjects: 243
Study 33899261 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care programme (Control)
Number of subjects: 243
Study 32000738 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced group (culturally tailored diabetes prevention program addressing psychosocial stressors)
Number of subjects: 207
Study 32000738 — intervention group
Group type: COMPARATOR
Intervention: Standard group (culturally tailored diabetes prevention program)
Number of subjects: 207
Study 32000738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 207
Study 36324443 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariate Cox regression model to predict cancer-specific survival (CSS)
Number of subjects: 619
Study 36324443 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariate Cox regression model to predict CSS
Number of subjects: 619
Study 33452773 — intervention group
Group type: EXPERIMENTAL
Intervention: Suctioning first
Number of subjects: 154
Study 33452773 — intervention group
Group type: COMPARATOR
Intervention: Drying first
Number of subjects: 154
Study 34034603 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with psychologist (n = 41)
Number of subjects: 88
Study 34034603 — intervention group
Group type: COMPARATOR
Intervention: PFMT treatment as usual (n = 47)
Number of subjects: 88
Study 33180967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Operating Microscope (DOM)
Number of subjects: 17
Study 33180967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Loupes
Number of subjects: 17
Study 33180967 — intervention group
Group type: COMPARATOR
Intervention: No Magnification (Control)
Number of subjects: 17
Study 34580881 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing group (traced characters on paper with a ballpoint pen for 15 min/day for 10 days)
Number of subjects: 60
Study 34580881 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg group (used a pegboard for 15 min/day for 10 days)
Number of subjects: 60
Study 34580881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 32763103 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of a copy of the patient's medical notes on admission and discharge, along with a plain English statement about their medical condition and a detailed care plan.
Number of subjects: 200
Study 32763103 — intervention group
Group type: COMPARATOR
Intervention: Standard care (verbal information)
Number of subjects: 200
Study 35589346 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (neonates)
Number of subjects: 59729
Study 35589346 — intervention group
Group type: COMPARATOR
Intervention: Girls (neonates)
Number of subjects: 59729
Study 32648072 — intervention group
Group type: COMPARATOR
Intervention: Patiromer
Number of subjects: 295
Study 32648072 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone with Patiromer
Number of subjects: 295
Study 34530172 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 214
Study 34530172 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 214
Study 34530172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Diet
Number of subjects: 128
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) - high meal frequency
Number of subjects: 128
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) - physical activity
Number of subjects: 128
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure interventions
Number of subjects: 128
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased albuminuria
Number of subjects: 128
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 128
Study 33672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure increase (400 kcal/70 kg)
Number of subjects: 128
Study 36100886 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece device with a PIP of 30 cmH2O and positive end-expiratory airway pressure of 5 cmH2O
Number of subjects: 23
Study 34039406 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, low-cost, and accessible pulmonary rehabilitation program with weekly physiotherapist supervision
Number of subjects: 50
Study 34039406 — intervention group
Group type: COMPARATOR
Intervention: Individualized, low-cost, and accessible pulmonary rehabilitation program without weekly physiotherapist supervision
Number of subjects: 50
Study 34182829 — intervention group
Group type: EXPERIMENTAL
Intervention: DLMOff model
Number of subjects: 16
Study 34182829 — intervention group
Group type: EXPERIMENTAL
Intervention: DLMO model
Number of subjects: 16
Study 34290290 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation
Number of subjects: 0
Study 34290290 — intervention group
Group type: COMPARATOR
Intervention: Control for genetic influences on covariates (cannabis and alcohol use, risk‐taking, insomnia)
Number of subjects: 0
Study 34108383 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ART (mART)
Number of subjects: 2431
Study 34108383 — intervention group
Group type: COMPARATOR
Intervention: Infant nevirapine prophylaxis (iNVP)
Number of subjects: 2431